Applied DNA Sciences announced on September 18, 2024, that it has regained compliance with Nasdaq's minimum bid price requirement. The company received notification from Nasdaq on September 17, 2024, confirming that its common stock maintained a closing bid price of $1.00 or greater for 20 consecutive business days from August 19 to September 16, 2024.This development resolves the compliance issue raised on July 12, 2024, when Applied DNA was notified of failing to maintain the minimum $1.00 bid price over 30 consecutive business days. The company's successful compliance with the minimum bid price rule ensures its continued listing on the Nasdaq Capital Market, with Nasdaq considering the matter closed.Applied DNA Sciences, a biotechnology company specializing in PCR-based DNA technologies, operates in three primary business markets: enzymatic manufacture of synthetic DNA, detection of DNA and RNA in molecular diagnostics, and DNA manufacture and detection for industrial supply chain security services.

Applied DNA Sciences announced on September 18, 2024, that it has regained compliance with Nasdaq's minimum bid price requirement. The company received notification from Nasdaq on September 17, 2024, confirming that its common stock maintained a closing bid price of $1.00 or greater for 20 consecutive business days from August 19 to September 16, 2024.This development resolves the compliance issue raised on July 12, 2024, when Applied DNA was notified of failing to maintain the minimum $1.00 bid price over 30 consecutive business days. The company's successful compliance with the minimum bid price rule ensures its continued listing on the Nasdaq Capital Market, with Nasdaq considering the matter closed.Applied DNA Sciences, a biotechnology company specializing in PCR-based DNA technologies, operates in three primary business markets: enzymatic manufacture of synthetic DNA, detection of DNA and RNA in molecular diagnostics, and DNA manufacture and detection for industrial supply chain security services.